KIN
Undervalued by 3.2% based on the discounted cash flow analysis.
Market cap | $0.00 |
---|---|
Enterprise Value | $-23,489,000.00 |
Dividend Yield | $0 (0%) |
Earnings per Share | $-0.6 |
Beta | 1.32 |
Outstanding Shares | 45,277,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -15.38 |
---|---|
PEG | 10.96 |
Price to Sales | - |
Price to Book Ratio | 9.25 |
Enterprise Value to Revenue | -2.96 |
Enterprise Value to EBIT | 0.58 |
Enterprise Value to Net Income | 0 |
Total Debt to Enterprise | -0.99 |
Debt to Equity | 0.29 |
No data
No data
Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family member...